Related Experiment Videos
Some recent data on chemical protection against ionizing radiation
1Unité de Radioprotection, Centre de Recherches du Service de Santé des Armées, Grenoble, La Tronche, France.
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)
|January 1, 1992
Summary
Incorporating radioprotectors like cysteamine into liposomes or microspheres enhances their stability and prolongs their protective effects against radiation. This delivery method improves plasma concentration and allows for sustained radioprotective activity after oral administration.
Area of Science:
- Pharmacology
- Radioprotection
- Drug Delivery Systems
Background:
- Radioprotectors face rapid degradation, toxicity, and short action duration after oral delivery.
- Developing effective delivery systems is crucial for enhancing radioprotector efficacy and stability.
Purpose of the Study:
- To investigate the radioprotective efficacy of cysteamine and WR-2721 when incorporated into delivery vectors.
- To evaluate the stability, duration of action, and pharmacokinetic profile of encapsulated radioprotectors.
Main Methods:
- Oral administration of cysteamine-liposomal suspension and WR-2721-microspheres.
- Utilizing 35S-cysteamine to track plasmatic concentration.
- Assessing radioprotective activity duration and conservation methods (freeze-drying).
Main Results:
- Cysteamine-liposomal suspension provided radioprotective activity for approximately 4 hours.
- Encapsulation increased cysteamine's plasmatic concentration.
- Freeze-drying at 4°C proved effective for sample conservation.
- Microsphere-encapsulated WR-2721 also demonstrated sustained radioprotective activity.
- Aminothiols can be entrapped in liposomes, reducing oxygen diffusion in lipid bilayers.
Conclusions:
- Liposomal and microsphere encapsulation significantly improves radioprotector stability and oral bioavailability.
- These delivery systems offer a promising strategy for sustained and effective radioprotection.
- Understanding drug-vehicle interactions is key to optimizing liposomal drug delivery.